世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
抗VEGF薬に関する市場調査：血管内皮増殖因子A阻害薬が市場シェアの半分近くを占めるMarket Study on Anti-VEGF: Close to Half of the Market Share Accounted for by Vascular Endothelial Growth Factor-A inhibitors 抗VEGF市場：報告書の範囲 Persistence Market Research社の調査レポート「世界の抗VEGF市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応するセクションに関する詳細な分析、および最新情報を... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー抗VEGF市場：報告書の範囲Persistence Market Research社の調査レポート「世界の抗VEGF市場」は、機会や現在の市場環境を評価し、市場に影響を与える対応するセクションに関する詳細な分析、および最新情報を提供します。この調査は、市場の促進要因、阻害要因、動向、機会を含む現在の市場力学に関する詳細な洞察を提供します。この市場調査の主な目的は、2023年から2033年の予測期間中に市場がどのように推移するかについての独占情報を提示することです。 市場の成功的な成長のための重要な指標は、市場の前年比（YoY）成長分析、複合年間成長率（CAGR）を含むこの包括的なレポートで提示され、Persistence Market Research社の調査で網羅的に説明されています。この調査研究は、抗VEGF製品の需要と調査期間中の定量的な開発機会を知るために読者をサポートすることができます。 この調査は、投資家、メーカー、サービスプロバイダー、流通業者、サプライヤーなどの景観の株主にとって有益であり、抗VEGF市場で繁栄するために適切なビジネス戦略を開発するのに役立ちます。抗VEGF市場の株主、業界専門家、投資家、研究者、記者、ビジネス愛好家は、このPersistence Market Researchの調査で示された洞察と情報を活用できます。 市場統計、および抗VEGF市場のビジネスシナリオに影響を与えるマクロ経済変数だけでなくミクロ経済変数に関連する情報も、現在の研究に含まれています。市場の潜在的な発展に応じて、実質的な洞察も本レポートで遭遇します。さらに、本レポートで提出されたデータにより、業界のマイナーな企業や新規参入者は、市場で牽引力を発揮するために適切な企業選択をする際に役立つことができます。 主要な市場セグメント Persistence Market Research社の抗VEGF市場に関する調査レポートは、薬剤、タイプ、疾患適応、流通チャネル、地域の5つの重要なセグメントに分けられた情報を提供しています。本レポートでは、これらのカテゴリーに関連する重要な市場力学と成長パラメータに関する包括的なデータと情報を提供します。 薬剤 低分子化合物 パゾパニブ スニチニブ ソラフェニブ レゴラフェニブ カボザンチニブ レンバチニブ ポナチニブ カボザンチニブ アクシチニブ チボザニブ バンデタニブ アンロチニブ アパチニブ フルクインチニブ スルファチニブ 生物学的製剤 ベバシズマブ アフリベルセプト ラムシルマブ タイプ VEGF A阻害剤 VEGF B阻害剤 VEGF-C阻害剤 プラセンタ成長因子阻害剤 疾患別適応症 がん領域 非小細胞肺がん 腎細胞がん 大腸がん 肝細胞がん 子宮頸がん その他 血液疾患 眼科疾患 加齢黄斑変性（AMD） 糖尿病性網膜症 その他 販売チャネル 病院 専門医院 通信販売薬局 地域 北アメリカ 中南米 ヨーロッパ 南アジア 東アジア オセアニア 中東・アフリカ(MEA) 報告書に記載されている主な質問 今後数年間、抗VEGF薬で最も収益性の高い市場を維持し続けるのはどの地域か？ トレンドの変化は市場にどのような影響を与えるか？ COVID-19危機は市場成長にどのような影響を与えたか？ 市場関係者はどのようにして先進国の低空飛行の機会を獲得することができるのか？ 市場関係者は、このランドスケープにおける自らのポジションを形成するために、どのような戦略を持っているのか？ 投資家が市場に投資する際に認識する必要があり、取り組む可能性のある抑制要因とは？ 市場に影響を与える開発トレンドは何か？ 抗VEGF市場の企業は、先進国や新興国における成長機会をどのように利用できるのか？ 調査方法 Persistence Market Research社の調査レポートでは、抗VEGF市場の成長に関する広範な調査を実施し、市場の将来の成長パラメータに関する結論に達するために、独自の調査手法を活用しています。この調査手法は、一次調査と二次調査の組み合わせであり、アナリストが結論の正確性と信頼性を確保するのに役立ちます。 市場調査の作成中にアナリストが参照した二次資料には、政府機関の統計、業界誌、白書、社内外の独自データベースなどがあります。アナリストは、一次資料として、本レポートの作成に貢献したシニアマネージャー、製品ポートフォリオマネージャー、CEO、副社長、マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャーにインタビューを行った。 一次および二次リソースから取得した包括的な情報は、市場内の企業からの検証として機能し、抗VEGF市場の成長見通しに関するPersistence Market Researchの予測をより正確で信頼できるものにします。 目次1. Executive Summary1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage/Taxonomy 2.2. Market Definition/Scope/Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Regulatory Landscape 4.2. Pipeline Assessment 4.3. Product Adoption and Usage Analysis 4.4. Key Marketing & Promotional Strategies Adopted by Companies 4.5. PESTLE Analysis 4.6. Porters Analysis 4.7. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Spending Outlook 5.1.3. Global Oncology Therapeutic Medicines Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increase in R&D Funding and Grants 5.2.2. Rising Research Activities for Rare Disease Indications 5.2.3. High Demand for Biologics 5.2.4. Surge in Research Collaborations for Development of Drugs 5.2.5. High Prevalence of Cancer 5.2.6. New Product Launch 5.2.7. Regulatory Approvals 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Drug Types 6.1.2. Revenue By Types 6.1.3. Revenue By Disease Indication 6.1.4. Revenue By Distribution Channel 6.1.5. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012–2022 and Forecast, 2023–2033 7.1. Historical Market Value (US$ Mn) Analysis, 2012–2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023–2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Drug Types 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Types, 2012–2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Types, 2023–2033 8.3.1. Small Molecules 8.3.1.1. Pazopanib 8.3.1.2. Sunitinib 8.3.1.3. Regorafenib 8.3.1.4. Cabozantinib 8.3.1.5. Lenvatinib 8.3.1.6. Ponatinib 8.3.1.7. Cabozantinib 8.3.1.8. Axitinib 8.3.1.9. Tivozanib 8.3.1.10. Vandetanib 8.3.1.11. Sorafenib 8.3.1.12. Anlotinib 8.3.1.13. Apatinib 8.3.1.14. Fruquintinib 8.3.1.15. Surufatinib 8.3.2. Biologics 8.3.2.1. Bevacizumab 8.3.2.2. Ziv-Aflibercept 8.3.2.3. Ramucirumab 8.3.2.4. Ranibizumab 8.4. Market Attractiveness Analysis By Drug Types 9. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Types 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis, By Types, 2012–2022 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types, 2023–2033 9.3.1. VEGF A Inhibitors 9.3.2. VEGF B Inhibitors 9.3.3. VEGF C Inhibitors 9.3.4. Placenta Growth Factor Inhibitors 9.4. Market Attractiveness Analysis By Types 10. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Disease Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2012–2022 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2023–2033 10.3.1. Oncology 10.3.1.1. Cervical Cancer 10.3.1.2. Non-Small Cell Lung Cancer 10.3.1.3. Renal Cell Carcinoma 10.3.1.4. Soft Tissue Sarcoma 10.3.1.5. Colorectal Cancer 10.3.1.6. Liver Cancer 10.3.1.7. Others 10.3.2. Hematology Disorders 10.3.3. Ophthalmology Disorders 10.3.3.1. Wet Age-Related Macular Degeneration (AMD) 10.3.3.2. Diabetic Retinopathy 10.3.3.3. Others 10.4. Market Attractiveness Analysis By Disease Indication 11. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2012–2022 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023–2033 11.3.1. Hospitals 11.3.2. Specialty Clinics 11.3.3. Cancer Research Centers 11.3.4. Mail Order Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2012–2022 and Forecast 2023–2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2022 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023–2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2012–2022 and Forecast 2023–2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Drug Types 13.3.3. By Types 13.3.4. By Disease Indication 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Types 13.4.3. By Types 13.4.4. By Disease Indication 13.4.5. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. U.S. Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Drug Types 13.8.1.2.2. By Types 13.8.1.2.3. By Disease Indication 13.8.1.2.4. By Distribution Channel 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Drug Types 13.8.2.2.2. By Types 13.8.2.2.3. By Disease Indication 13.8.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2012–2022 and Forecast 2023–2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug Types 14.3.3. By Types 14.3.4. By Disease Indication 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Types 14.4.3. By Types 14.4.4. By Disease Indication 14.4.5. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug Types 14.8.1.2.2. By Types 14.8.1.2.3. By Disease Indication 14.8.1.2.4. By Distribution Channel 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Drug Types 14.8.2.2.2. By Types 14.8.2.2.3. By Disease Indication 14.8.2.2.4. By Distribution Channel 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Drug Types 14.8.3.2.2. By Types 14.8.3.2.3. By Disease Indication 14.8.3.2.4. By Distribution Channel 15. Europe Market Analysis 2012–2022 and Forecast 2023–2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Russia 15.3.1.9. Rest of Europe 15.3.2. By Drug Types 15.3.3. By Types 15.3.4. By Disease Indication 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Types 15.4.3. By Types 15.4.4. By Disease Indication 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug Types 15.8.1.2.2. By Types 15.8.1.2.3. By Disease Indication 15.8.1.2.4. By Distribution Channel 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug Types 15.8.2.2.2. By Types 15.8.2.2.3. By Disease Indication 15.8.2.2.4. By Distribution Channel 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Drug Types 15.8.3.2.2. By Types 15.8.3.2.3. By Disease Indication 15.8.3.2.4. By Distribution Channel 15.8.4. U.K. Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Drug Types 15.8.4.2.2. By Types 15.8.4.2.3. By Disease Indication 15.8.4.2.4. By Distribution Channel 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Drug Types 15.8.5.2.2. By Types 15.8.5.2.3. By Disease Indication 15.8.5.2.4. By Distribution Channel 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Drug Types 15.8.6.2.2. By Types 15.8.6.2.3. By Disease Indication 15.8.6.2.4. By Distribution Channel 15.8.7. Nordic Countries Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Drug Types 15.8.7.2.2. By Types 15.8.7.2.3. By Disease Indication 15.8.7.2.4. By Distribution Channel 15.8.8. Russia Market Analysis 15.8.8.1. Introduction 15.8.8.2. Market Analysis and Forecast by Market Taxonomy 15.8.8.2.1. By Drug Types 15.8.8.2.2. By Types 15.8.8.2.3. By Disease Indication 15.8.8.2.4. By Distribution Channel 16. East Asia Market Analysis 2012–2022 and Forecast 2023–2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug Types 16.3.3. By Types 16.3.4. By Disease Indication 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Types 16.4.3. By Types 16.4.4. By Disease Indication 16.4.5. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug Types 16.8.1.2.2. By Types 16.8.1.2.3. By Disease Indication 16.8.1.2.4. By Distribution Channel 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug Types 16.8.2.2.2. By Types 16.8.2.2.3. By Disease Indication 16.8.2.2.4. By Distribution Channel 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug Types 16.8.3.2.2. By Types 16.8.3.2.3. By Disease Indication 16.8.3.2.4. By Distribution Channel 17. South Asia Market Analysis 2012–2022 and Forecast 2023–2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Drug Types 17.3.3. By Types 17.3.4. By Disease Indication 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Types 17.4.3. By Types 17.4.4. By Disease Indication 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug Types 17.8.1.2.2. By Types 17.8.1.2.3. By Disease Indication 17.8.1.2.4. By Distribution Channel 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug Types 17.8.2.2.2. By Types 17.8.2.2.3. By Disease Indication 17.8.2.2.4. By Distribution Channel 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Drug Types 17.8.3.2.2. By Types 17.8.3.2.3. By Disease Indication 17.8.3.2.4. By Distribution Channel 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Drug Types 17.8.4.2.2. By Types 17.8.4.2.3. By Disease Indication 17.8.4.2.4. By Distribution Channel 18. Oceania Market 2012-2022 and Forecast 2023-2033 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug Types 18.3.3. By Types 18.3.4. By Disease Indication 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Types 18.4.3. By Types 18.4.4. By Disease Indication 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. Australia Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug Types 18.8.1.2.2. By Types 18.8.1.2.3. By Disease Indication 18.8.1.2.4. By Distribution Channel 18.8.2. New Zealand Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug Types 18.8.2.2.2. By Types 18.8.2.2.3. By Disease Indication 18.8.2.2.4. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2012–2022 and Forecast 2023–2033 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Drug Types 19.3.3. By Types 19.3.4. By Disease Indication 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Types 19.4.3. By Types 19.4.4. By Disease Indication 19.4.5. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Drug Types 19.8.1.2.2. By Types 19.8.1.2.3. By Disease Indication 19.8.1.2.4. By Distribution Channel 19.8.2. Türkiye Anti-VEGF Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Drug Types 19.8.2.2.2. By Types 19.8.2.2.3. By Disease Indication 19.8.2.2.4. By Distribution Channel 19.8.3. South Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Drug Types 19.8.3.2.2. By Types 19.8.3.2.3. By Disease Indication 19.8.3.2.4. By Distribution Channel 19.8.4. North Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Drug Types 19.8.4.2.2. By Types 19.8.4.2.3. By Disease Indication 19.8.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Concentration 20.4. Market Presence Analysis 20.4.1. Regional Footprint Analysis 20.4.2. Channel Footprint Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Sales Footprint 21.3.1.4. Key Financial 21.3.1.5. Key Developments 21.3.1.6. SWOT Analysis 21.3.1.7. Strategy Overview 21.3.1.7.1. Marketing Strategies 21.3.1.7.2. Channel Strategies 21.3.2. Bayer AG 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Sales Footprint 21.3.2.4. Key Financial 21.3.2.5. Key Developments 21.3.2.6. SWOT Analysis 21.3.2.7. Strategy Overview 21.3.2.7.1. Marketing Strategies 21.3.2.7.2. Channel Strategies 21.3.3. Novartis AG 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Sales Footprint 21.3.3.4. Key Financial 21.3.3.5. Key Developments 21.3.3.6. SWOT Analysis 21.3.3.7. Strategy Overview 21.3.3.7.1. Marketing Strategies 21.3.3.7.2. Channel Strategies 21.3.4. Sanofi SA 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Sales Footprint 21.3.4.4. Key Financial 21.3.4.5. Key Developments 21.3.4.6. SWOT Analysis 21.3.4.7. Strategy Overview 21.3.4.7.1. Marketing Strategies 21.3.4.7.2. Channel Strategies 21.3.5. Exelixis Inc. 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Sales Footprint 21.3.5.4. Key Financial 21.3.5.5. Key Developments 21.3.5.6. SWOT Analysis 21.3.5.7. Strategy Overview 21.3.5.7.1. Marketing Strategies 21.3.5.7.2. Channel Strategies 21.3.6. Eisai Co. Ltd. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Sales Footprint 21.3.6.4. Key Financial 21.3.6.5. Key Developments 21.3.6.6. SWOT Analysis 21.3.6.7. Strategy Overview 21.3.6.7.1. Marketing Strategies 21.3.6.7.2. Channel Strategies 21.3.7. Amgen Inc. 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Sales Footprint 21.3.7.4. Key Financial 21.3.7.5. Key Developments 21.3.7.6. SWOT Analysis 21.3.7.7. Strategy Overview 21.3.7.7.1. Marketing Strategies 21.3.7.7.2. Channel Strategies 21.3.8. F. Hoffmann-La Roche Ltd. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Sales Footprint 21.3.8.4. Key Financial 21.3.8.5. Key Developments 21.3.8.6. SWOT Analysis 21.3.8.7. Strategy Overview 21.3.8.7.1. Marketing Strategies 21.3.8.7.2. Channel Strategies 21.3.9. Eli Lilly and Company 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Sales Footprint 21.3.9.4. Key Financial 21.3.9.5. Key Developments 21.3.9.6. SWOT Analysis 21.3.9.7. Strategy Overview 21.3.9.7.1. Marketing Strategies 21.3.9.7.2. Channel Strategies 21.3.10. Amneal Pharmaceuticals Inc. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Sales Footprint 21.3.10.4. Key Financial 21.3.10.5. Key Developments 21.3.10.6. SWOT Analysis 21.3.10.7. Strategy Overview 21.3.10.7.1. Marketing Strategies 21.3.10.7.2. Channel Strategies 21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Sales Footprint 21.3.11.4. Key Financial 21.3.11.5. Key Developments 21.3.11.6. SWOT Analysis 21.3.11.7. Strategy Overview 21.3.11.7.1. Marketing Strategies 21.3.11.7.2. Channel Strategies 21.3.12. Takeda Pharmaceutical Co. Ltd. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Sales Footprint 21.3.12.4. Key Financial 21.3.12.5. Key Developments 21.3.12.6. SWOT Analysis 21.3.12.7. Strategy Overview 21.3.12.7.1. Marketing Strategies 21.3.12.7.2. Channel Strategies 21.3.13. Sino Biopharma 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Sales Footprint 21.3.13.4. Key Financial 21.3.13.5. Key Developments 21.3.13.6. SWOT Analysis 21.3.13.7. Strategy Overview 21.3.13.7.1. Marketing Strategies 21.3.13.7.2. Channel Strategies 21.3.14. HUTCHMED 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Sales Footprint 21.3.14.4. Key Financial 21.3.14.5. Key Developments 21.3.14.6. SWOT Analysis 21.3.14.7. Strategy Overview 21.3.14.7.1. Marketing Strategies 21.3.14.7.2. Channel Strategies 22. Assumptions and Acronyms Used 23. Research Methodology
SummaryAnti-VEGF Market: Scope of the Report Table of Contents1. Executive Summary1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage/Taxonomy 2.2. Market Definition/Scope/Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Regulatory Landscape 4.2. Pipeline Assessment 4.3. Product Adoption and Usage Analysis 4.4. Key Marketing & Promotional Strategies Adopted by Companies 4.5. PESTLE Analysis 4.6. Porters Analysis 4.7. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Spending Outlook 5.1.3. Global Oncology Therapeutic Medicines Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increase in R&D Funding and Grants 5.2.2. Rising Research Activities for Rare Disease Indications 5.2.3. High Demand for Biologics 5.2.4. Surge in Research Collaborations for Development of Drugs 5.2.5. High Prevalence of Cancer 5.2.6. New Product Launch 5.2.7. Regulatory Approvals 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Drug Types 6.1.2. Revenue By Types 6.1.3. Revenue By Disease Indication 6.1.4. Revenue By Distribution Channel 6.1.5. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012–2022 and Forecast, 2023–2033 7.1. Historical Market Value (US$ Mn) Analysis, 2012–2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023–2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Drug Types 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Types, 2012–2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Types, 2023–2033 8.3.1. Small Molecules 8.3.1.1. Pazopanib 8.3.1.2. Sunitinib 8.3.1.3. Regorafenib 8.3.1.4. Cabozantinib 8.3.1.5. Lenvatinib 8.3.1.6. Ponatinib 8.3.1.7. Cabozantinib 8.3.1.8. Axitinib 8.3.1.9. Tivozanib 8.3.1.10. Vandetanib 8.3.1.11. Sorafenib 8.3.1.12. Anlotinib 8.3.1.13. Apatinib 8.3.1.14. Fruquintinib 8.3.1.15. Surufatinib 8.3.2. Biologics 8.3.2.1. Bevacizumab 8.3.2.2. Ziv-Aflibercept 8.3.2.3. Ramucirumab 8.3.2.4. Ranibizumab 8.4. Market Attractiveness Analysis By Drug Types 9. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Types 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis, By Types, 2012–2022 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types, 2023–2033 9.3.1. VEGF A Inhibitors 9.3.2. VEGF B Inhibitors 9.3.3. VEGF C Inhibitors 9.3.4. Placenta Growth Factor Inhibitors 9.4. Market Attractiveness Analysis By Types 10. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Disease Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2012–2022 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2023–2033 10.3.1. Oncology 10.3.1.1. Cervical Cancer 10.3.1.2. Non-Small Cell Lung Cancer 10.3.1.3. Renal Cell Carcinoma 10.3.1.4. Soft Tissue Sarcoma 10.3.1.5. Colorectal Cancer 10.3.1.6. Liver Cancer 10.3.1.7. Others 10.3.2. Hematology Disorders 10.3.3. Ophthalmology Disorders 10.3.3.1. Wet Age-Related Macular Degeneration (AMD) 10.3.3.2. Diabetic Retinopathy 10.3.3.3. Others 10.4. Market Attractiveness Analysis By Disease Indication 11. Global Market Analysis 2012–2022 and Forecast 2023–2033, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2012–2022 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023–2033 11.3.1. Hospitals 11.3.2. Specialty Clinics 11.3.3. Cancer Research Centers 11.3.4. Mail Order Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2012–2022 and Forecast 2023–2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2022 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023–2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2012–2022 and Forecast 2023–2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Drug Types 13.3.3. By Types 13.3.4. By Disease Indication 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Types 13.4.3. By Types 13.4.4. By Disease Indication 13.4.5. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. U.S. Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Drug Types 13.8.1.2.2. By Types 13.8.1.2.3. By Disease Indication 13.8.1.2.4. By Distribution Channel 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Drug Types 13.8.2.2.2. By Types 13.8.2.2.3. By Disease Indication 13.8.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2012–2022 and Forecast 2023–2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug Types 14.3.3. By Types 14.3.4. By Disease Indication 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Types 14.4.3. By Types 14.4.4. By Disease Indication 14.4.5. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug Types 14.8.1.2.2. By Types 14.8.1.2.3. By Disease Indication 14.8.1.2.4. By Distribution Channel 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Drug Types 14.8.2.2.2. By Types 14.8.2.2.3. By Disease Indication 14.8.2.2.4. By Distribution Channel 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Drug Types 14.8.3.2.2. By Types 14.8.3.2.3. By Disease Indication 14.8.3.2.4. By Distribution Channel 15. Europe Market Analysis 2012–2022 and Forecast 2023–2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Russia 15.3.1.9. Rest of Europe 15.3.2. By Drug Types 15.3.3. By Types 15.3.4. By Disease Indication 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Types 15.4.3. By Types 15.4.4. By Disease Indication 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug Types 15.8.1.2.2. By Types 15.8.1.2.3. By Disease Indication 15.8.1.2.4. By Distribution Channel 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug Types 15.8.2.2.2. By Types 15.8.2.2.3. By Disease Indication 15.8.2.2.4. By Distribution Channel 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Drug Types 15.8.3.2.2. By Types 15.8.3.2.3. By Disease Indication 15.8.3.2.4. By Distribution Channel 15.8.4. U.K. Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Drug Types 15.8.4.2.2. By Types 15.8.4.2.3. By Disease Indication 15.8.4.2.4. By Distribution Channel 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Drug Types 15.8.5.2.2. By Types 15.8.5.2.3. By Disease Indication 15.8.5.2.4. By Distribution Channel 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Drug Types 15.8.6.2.2. By Types 15.8.6.2.3. By Disease Indication 15.8.6.2.4. By Distribution Channel 15.8.7. Nordic Countries Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Drug Types 15.8.7.2.2. By Types 15.8.7.2.3. By Disease Indication 15.8.7.2.4. By Distribution Channel 15.8.8. Russia Market Analysis 15.8.8.1. Introduction 15.8.8.2. Market Analysis and Forecast by Market Taxonomy 15.8.8.2.1. By Drug Types 15.8.8.2.2. By Types 15.8.8.2.3. By Disease Indication 15.8.8.2.4. By Distribution Channel 16. East Asia Market Analysis 2012–2022 and Forecast 2023–2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug Types 16.3.3. By Types 16.3.4. By Disease Indication 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Types 16.4.3. By Types 16.4.4. By Disease Indication 16.4.5. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug Types 16.8.1.2.2. By Types 16.8.1.2.3. By Disease Indication 16.8.1.2.4. By Distribution Channel 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug Types 16.8.2.2.2. By Types 16.8.2.2.3. By Disease Indication 16.8.2.2.4. By Distribution Channel 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug Types 16.8.3.2.2. By Types 16.8.3.2.3. By Disease Indication 16.8.3.2.4. By Distribution Channel 17. South Asia Market Analysis 2012–2022 and Forecast 2023–2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Drug Types 17.3.3. By Types 17.3.4. By Disease Indication 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Types 17.4.3. By Types 17.4.4. By Disease Indication 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug Types 17.8.1.2.2. By Types 17.8.1.2.3. By Disease Indication 17.8.1.2.4. By Distribution Channel 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug Types 17.8.2.2.2. By Types 17.8.2.2.3. By Disease Indication 17.8.2.2.4. By Distribution Channel 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Drug Types 17.8.3.2.2. By Types 17.8.3.2.3. By Disease Indication 17.8.3.2.4. By Distribution Channel 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Drug Types 17.8.4.2.2. By Types 17.8.4.2.3. By Disease Indication 17.8.4.2.4. By Distribution Channel 18. Oceania Market 2012-2022 and Forecast 2023-2033 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug Types 18.3.3. By Types 18.3.4. By Disease Indication 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Types 18.4.3. By Types 18.4.4. By Disease Indication 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. Australia Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug Types 18.8.1.2.2. By Types 18.8.1.2.3. By Disease Indication 18.8.1.2.4. By Distribution Channel 18.8.2. New Zealand Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug Types 18.8.2.2.2. By Types 18.8.2.2.3. By Disease Indication 18.8.2.2.4. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2012–2022 and Forecast 2023–2033 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2022 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023–2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Drug Types 19.3.3. By Types 19.3.4. By Disease Indication 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Types 19.4.3. By Types 19.4.4. By Disease Indication 19.4.5. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Drug Types 19.8.1.2.2. By Types 19.8.1.2.3. By Disease Indication 19.8.1.2.4. By Distribution Channel 19.8.2. Türkiye Anti-VEGF Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Drug Types 19.8.2.2.2. By Types 19.8.2.2.3. By Disease Indication 19.8.2.2.4. By Distribution Channel 19.8.3. South Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Drug Types 19.8.3.2.2. By Types 19.8.3.2.3. By Disease Indication 19.8.3.2.4. By Distribution Channel 19.8.4. North Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Drug Types 19.8.4.2.2. By Types 19.8.4.2.3. By Disease Indication 19.8.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Concentration 20.4. Market Presence Analysis 20.4.1. Regional Footprint Analysis 20.4.2. Channel Footprint Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Sales Footprint 21.3.1.4. Key Financial 21.3.1.5. Key Developments 21.3.1.6. SWOT Analysis 21.3.1.7. Strategy Overview 21.3.1.7.1. Marketing Strategies 21.3.1.7.2. Channel Strategies 21.3.2. Bayer AG 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Sales Footprint 21.3.2.4. Key Financial 21.3.2.5. Key Developments 21.3.2.6. SWOT Analysis 21.3.2.7. Strategy Overview 21.3.2.7.1. Marketing Strategies 21.3.2.7.2. Channel Strategies 21.3.3. Novartis AG 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Sales Footprint 21.3.3.4. Key Financial 21.3.3.5. Key Developments 21.3.3.6. SWOT Analysis 21.3.3.7. Strategy Overview 21.3.3.7.1. Marketing Strategies 21.3.3.7.2. Channel Strategies 21.3.4. Sanofi SA 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Sales Footprint 21.3.4.4. Key Financial 21.3.4.5. Key Developments 21.3.4.6. SWOT Analysis 21.3.4.7. Strategy Overview 21.3.4.7.1. Marketing Strategies 21.3.4.7.2. Channel Strategies 21.3.5. Exelixis Inc. 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Sales Footprint 21.3.5.4. Key Financial 21.3.5.5. Key Developments 21.3.5.6. SWOT Analysis 21.3.5.7. Strategy Overview 21.3.5.7.1. Marketing Strategies 21.3.5.7.2. Channel Strategies 21.3.6. Eisai Co. Ltd. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Sales Footprint 21.3.6.4. Key Financial 21.3.6.5. Key Developments 21.3.6.6. SWOT Analysis 21.3.6.7. Strategy Overview 21.3.6.7.1. Marketing Strategies 21.3.6.7.2. Channel Strategies 21.3.7. Amgen Inc. 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Sales Footprint 21.3.7.4. Key Financial 21.3.7.5. Key Developments 21.3.7.6. SWOT Analysis 21.3.7.7. Strategy Overview 21.3.7.7.1. Marketing Strategies 21.3.7.7.2. Channel Strategies 21.3.8. F. Hoffmann-La Roche Ltd. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Sales Footprint 21.3.8.4. Key Financial 21.3.8.5. Key Developments 21.3.8.6. SWOT Analysis 21.3.8.7. Strategy Overview 21.3.8.7.1. Marketing Strategies 21.3.8.7.2. Channel Strategies 21.3.9. Eli Lilly and Company 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Sales Footprint 21.3.9.4. Key Financial 21.3.9.5. Key Developments 21.3.9.6. SWOT Analysis 21.3.9.7. Strategy Overview 21.3.9.7.1. Marketing Strategies 21.3.9.7.2. Channel Strategies 21.3.10. Amneal Pharmaceuticals Inc. 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Sales Footprint 21.3.10.4. Key Financial 21.3.10.5. Key Developments 21.3.10.6. SWOT Analysis 21.3.10.7. Strategy Overview 21.3.10.7.1. Marketing Strategies 21.3.10.7.2. Channel Strategies 21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd. 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Sales Footprint 21.3.11.4. Key Financial 21.3.11.5. Key Developments 21.3.11.6. SWOT Analysis 21.3.11.7. Strategy Overview 21.3.11.7.1. Marketing Strategies 21.3.11.7.2. Channel Strategies 21.3.12. Takeda Pharmaceutical Co. Ltd. 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Sales Footprint 21.3.12.4. Key Financial 21.3.12.5. Key Developments 21.3.12.6. SWOT Analysis 21.3.12.7. Strategy Overview 21.3.12.7.1. Marketing Strategies 21.3.12.7.2. Channel Strategies 21.3.13. Sino Biopharma 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Sales Footprint 21.3.13.4. Key Financial 21.3.13.5. Key Developments 21.3.13.6. SWOT Analysis 21.3.13.7. Strategy Overview 21.3.13.7.1. Marketing Strategies 21.3.13.7.2. Channel Strategies 21.3.14. HUTCHMED 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Sales Footprint 21.3.14.4. Key Financial 21.3.14.5. Key Developments 21.3.14.6. SWOT Analysis 21.3.14.7. Strategy Overview 21.3.14.7.1. Marketing Strategies 21.3.14.7.2. Channel Strategies 22. Assumptions and Acronyms Used 23. Research Methodology
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Persistence Market Research社の医療・製薬・メディカルデバイス分野での最新刊レポート
本レポートと同じKEY WORD（inhibitors）の最新刊レポート
よくあるご質問Persistence Market Research社はどのような調査会社ですか?パーシスタンスマーケットリサーチ（Persistence Market Research/PMR）は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |
